MedPath

Study of the Effect of Water Soluble Oral Contrast (Gastrografin) on Postoperative Ileus After Colorectal Surgery

Phase 4
Completed
Conditions
Postoperative Ileus
Interventions
Drug: physiological serum
Registration Number
NCT01440712
Lead Sponsor
Hospital Universitari de Bellvitge
Brief Summary

The purpose of this trial is to determine whether the water-soluble contrast (gastrografin) is more effective in the treatment of postoperative ileus than the conventional one.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
58
Inclusion Criteria
  • All patients with postoperative ileus after colorectal surgery, defined as the presence from the third postoperative day, abdominal distension, nausea, vomiting with or without abdominal pain or discomfort by dilation of bowel loops, confirmed radiology of the abdomen, and which are: Age > 18 years Patients undergoing laparotomy or laparoscopy for the following variants of colorectal disease with or without stoma:

    1. Neoplasia.
    2. Inflammatory disease.
    3. Diverticular disease. Patients who have been treated with standard PCA as postoperative analgesia. Signed informed consent. Undergoing elective or scheduled
Exclusion Criteria
  • Patient's refusal to sign informed consent

  • Pregnancy or lactation

  • Hypersensitivity to iodinated contrast agents (it´s the only contraindication to oral Gastrografin) Presence of other problems that justify the etiology of postoperative ileus:

    1. Anastomotic leakages.
    2. Mesenteric vascular disease.
    3. Incarcerated hernias.
    4. Intra-abdominal abscesses or collections.
    5. Metabolic or electrolyte disturbances. If during the course of the study one of the reasons previously cited as the etiology of postoperative ileus is present, the patient shall also be excluded. Also excluded patients undergoing emergency surgery.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
physiological serumphysiological serumPatients included in this group will be treated with 100 ml of physiological serum 0,9% by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
GastrografinGastrografinPatients located in this group will be treated with the administration of 100 ml of gastrografin by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
Primary Outcome Measures
NameTimeMethod
Time to resolution of postoperative ileus after surgery defined as time to tolerance of oral intake of solid or semisolid foodWhile the patient is admitted to the hospital. An average of 11 days since the intervention.
Secondary Outcome Measures
NameTimeMethod
Presence of postoperative pain and analgesic requiredWhile the patient is admitted to the hospital. An average of 11 days since the intervention

Postoperative complications were assessed in the intervening period between the immediate postoperative phase and when the patient is discharged

Percentage of mortality during hospitalization.While the patient is admitted to the hospital. An average of 11 days since the intervention

Postoperative complications were assessed in the intervening period between the immediate postoperative phase and when the patient is discharged

Hospital stay after diagnosis of ileusWhile the patient is admitted to the hospital. An average of 11 days since the intervention.

Postoperative complications were assessed in the intervening period between the immediate postoperative phase and when the patient is discharged.

Percentage of patients requiring total parenteral nutrition.While the patient is admitted to the hospital. An average of 11 days since the intervention

Postoperative complications were assessed in the intervening period between the immediate postoperative phase and when the patient is discharged

© Copyright 2025. All Rights Reserved by MedPath